Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

233 Clinical Updates found
Charles Sawyers
AACR Project GENIE steering committee head and Chair of MSK’s Human Oncology and Pathogenesis Program, Dr. Charles Sawyers, discusses how the first batch of genomic sequencing data fulfills an unmet need in oncology.
HPV-Related Oropharynx Cancer
The incidence of mouth and throat cancer is on the rise due to oral transmission of the human papilloma virus, but the "silver lining" of this phenomenon is doctors at Memorial Sloan Kettering have significantly reduced the intensity of treatment while achieving excellent outcomes for these patients.
Cancer care patients maintaining physical activity
Despite the proven benefits of exercise, even while receiving cancer treatment, new research undertaken by Memorial Sloan Kettering’s Integrative Medicine Service, shows that the majority of cancer patients report significant decreases in their physical activity levels after their cancer diagnosis.
rehabilitation patient
Spinal metastasis is one of the main causes of morbidity in cancer patients, but despite recent studies showing the major benefits of rehabilitation in these cases, oncology teams often remain unclear on how and when to utilize these services.
Researchers in radiology at Memorial Sloan Kettering continue to assess multiple imaging methods in the quest to improve treatment options and success rates for patients with biliary cancers such as cholangiocarcinoma.
Memorial Sloan Kettering is one of only a few centers in the U.S. to employ liver-directed therapies – using hepatic arterial infusion (HAI) – in conjunction with a number of systemic agents.
Over the last decade radiation oncologists at Memorial Sloan Kettering have refined a technique that allows ablative doses of radiation to be delivered with low risk of toxicity to inoperable primary pancreas and liver tumors near critical organs.
Advances in diagnostic and imaging modalities are making it possible to detect complex melanoma earlier, with greater accuracy, and are helping guide surgical approaches and patient monitoring plans.
The decision as to whether to use high-dose iplimumab as an adjuvant treatment for melanoma is difficult and requires excellent communication between physician and patient.
Memorial Sloan Kettering’s Melanoma Disease Management Team understands the importance of helping these patients maximize the opportunities and overcome the challenges that arise in their lives.